MINIject® Shows 5-Year Efficacy in Glaucoma Treatment

Introduction

Glaucoma is a leading cause of irreversible blindness worldwide. Managing it can be challenging, especially with treatments that require daily eye drops or invasive surgery.

A promising solution is the MINIject® implant, which has shown sustained results over five years in the STAR-GLOBAL trial. This long-term data highlights its potential as a safer and more effective option for controlling intraocular pressure (IOP).

What Is MINIject®?

MINIject® is a minimally invasive glaucoma surgery (MIGS) device designed to lower eye pressure by improving the natural drainage of fluid in the eye.

Key Features

• Made from a soft, biocompatible material

• Implanted in the suprachoroidal space

• No need for conjunctival incision

• Designed for mild to moderate glaucoma

This approach reduces trauma and allows for faster recovery compared to traditional surgery.

STAR-GLOBAL Trial Results

The STAR-GLOBAL trial is a multicenter study that evaluated the safety and effectiveness of MINIject® over five years.

Main Findings

Sustained IOP Reduction

• Around 30% reduction in eye pressure from baseline

• Results remained stable over five years

Reduced Medication Use

• 78% of patients reduced or stopped glaucoma medications

• Improved convenience and treatment adherence

Strong Safety Profile

• No serious device-related complications

• Most side effects were mild and temporary

Corneal Safety

• No significant damage to corneal cells

• Supports long-term eye health

Why MINIject® Stands Out

Minimally Invasive

Unlike traditional surgery, MINIject® uses a small incision with less tissue disruption.

Preserves Future Options

It does not affect the conjunctiva, allowing for additional treatments if needed.

Faster Recovery

Patients can usually return to normal activities within a few days.

Effective for Common Cases

Works well for open-angle glaucoma, the most common type.

Patient and Doctor Insights

Patient Feedback

Many patients reported:

• Less dependence on eye drops

• Greater comfort

• Improved confidence in managing their condition

Clinical Perspective

Eye specialists consider MINIject® a strong option for patients who:

• Struggle with medication compliance

• Need a long-term solution with fewer risks

What’s Next for MINIject®?

The success of the five-year trial suggests a growing role for MINIject® in glaucoma care. Future developments may include:

• Use in more advanced glaucoma cases

• Combination with other treatments

• Earlier intervention to slow disease progression

Conclusion

The MINIject® implant offers a safe, effective, and long-lasting option for glaucoma treatment. With proven results over five years, it provides a less invasive alternative that reduces the need for daily medication.

As technology advances, solutions like MINIject® may help improve long-term outcomes and make glaucoma easier to manage for patients worldwide.